leisure time -WSS

leisure time

author：focus 2025-09-04 22:01:45 - browse：77847

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Some of the ways extreme heat will change life as we know it

entertainment

WSS

The EU Joint Clinical Assessment needs to live up to its promise

How climate

The EU Joint Clinical Assessment needs to live up to its promise

HHS leader on health, climate change and biopharma emissions

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

An innovative path out of biotech’s “valley of death”

focus

leisure time

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

First Opinion Podcast: Long Covid needs a new approach

Anesthesiologist group: stop taking Ozempic before surgery

HHS leader on health, climate change and biopharma emissions

BioMarin wins approval for gene therapy to treat hemophilia A

2023 STAT Wunderkinds: get to know the winners

Novavax promises a turnaround & Lilly roils the obesity market

Large hospital system sues Multiplan for low

Virginia high school admissions case could be legal follow

STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

Target recalls 2.2 million additional candles due to laceration, burn hazards

FDA warns J&J's Abiomed: We will regulate your software

Faced with fears of OxyContin misuse, sales reps touted its safety

Pharmacists can make shortage drugs, but at what cost?

Novo acquires Inversago for up to $1 billion

STAT Summit: GSK CEO on pharma giant's new direction

hotspot

entertainment

entertainment

knowledge